levocetirizine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics/cerebral (or peripheral) vasodilators 1566 130018-77-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • levocetirizine hydrochloride
  • xyzal
  • levocetirizine
  • levocetirizine dihydrochloride
  • (R)-cetirizine
  • levocetirizine HCl
  • Molecular weight: 388.89
  • Formula: C21H25ClN2O3
  • CLOGP: 2.08
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 53.01
  • ALOGS: -3.77
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 71 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.18 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
May 25, 2007 FDA UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 95.04 12.22 146 14085 117746 46554085
Allergic reaction to excipient 76.09 12.22 18 14213 301 46671530
Pruritus 55.48 12.22 181 14050 242171 46429660
Drug-induced liver injury 49.26 12.22 49 14182 25319 46646512
Anaphylactic reaction 48.78 12.22 70 14161 53042 46618789
Angioedema 37.81 12.22 53 14178 39289 46632542
Asthma 37.70 12.22 85 14146 91457 46580374
Sinusitis 36.24 12.22 104 14127 129664 46542167
Completed suicide 33.45 12.22 3 14228 145917 46525914
Nail growth abnormal 32.01 12.22 10 14221 489 46671342
Dermatitis contact 28.55 12.22 22 14209 8101 46663730
Eye oedema 28.51 12.22 12 14219 1383 46670448
Hepatitis chronic active 28.21 12.22 6 14225 60 46671771
Hepatitis cholestatic 27.75 12.22 20 14211 6657 46665174
Fixed eruption 26.62 12.22 10 14221 855 46670976
Alopecia areata 25.99 12.22 9 14222 609 46671222
Hepatic encephalopathy 24.25 12.22 22 14209 10135 46661696
Lymphorrhoea 23.42 12.22 5 14226 51 46671780
Erythema multiforme 23.13 12.22 21 14210 9683 46662148
Abortion induced 22.13 12.22 21 14210 10239 46661592
Death 21.29 12.22 44 14187 335504 46336327
Swelling face 19.35 12.22 47 14184 53012 46618819
Cytogenetic analysis abnormal 18.98 12.22 7 14224 569 46671262
Oculomucocutaneous syndrome 18.49 12.22 5 14226 146 46671685
Chest discomfort 18.44 12.22 65 14166 90204 46581627
Rheumatoid arthritis 18.38 12.22 28 14203 240187 46431644
Cholangiocarcinoma 17.97 12.22 8 14223 1056 46670775
Toxicity to various agents 17.88 12.22 23 14208 211743 46460088
Exposure during pregnancy 17.24 12.22 72 14159 108140 46563691
Erythema 16.15 12.22 86 14145 142734 46529097
Nasal congestion 15.84 12.22 41 14190 48072 46623759
Face oedema 15.78 12.22 24 14207 19129 46652702
Analgesic drug level increased 15.39 12.22 8 14223 1486 46670345
Cough 15.18 12.22 121 14110 230128 46441703
Arrhythmia 15.05 12.22 33 14198 34808 46637023
Infusion site swelling 14.91 12.22 13 14218 5686 46666145
Arthropathy 14.38 12.22 4 14227 84696 46587135
Abortion spontaneous 14.17 12.22 37 14194 43609 46628222
Joint swelling 14.05 12.22 18 14213 166055 46505776
Alopecia totalis 13.80 12.22 4 14227 151 46671680
Bronchitis 13.50 12.22 66 14165 105913 46565918
Infusion site erythema 13.44 12.22 14 14217 7628 46664203
Cholestasis 13.39 12.22 27 14204 26866 46644965
Bronchospasm 13.39 12.22 20 14211 15687 46656144
Vascular injury 13.16 12.22 6 14225 838 46670993
Coronavirus infection 13.07 12.22 9 14222 2785 46669046
Dyspnoea 13.07 12.22 225 14006 515323 46156508
Hyperventilation 13.03 12.22 12 14219 5635 46666196
Drug eruption 12.57 12.22 23 14208 21306 46650525
Upper respiratory tract infection 12.32 12.22 45 14186 63511 46608320
Psoriasis 12.28 12.22 52 14179 78552 46593279
Abortion missed 12.25 12.22 7 14224 1565 46670266

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal malformation 64.63 14.41 13 6543 139 29945783
Trisomy 18 58.55 14.41 13 6543 230 29945692
Drug-induced liver injury 42.36 14.41 36 6520 21238 29924684
Anaphylactic reaction 37.56 14.41 38 6518 27944 29917978
Pruritus 36.41 14.41 80 6476 118124 29827798
Alopecia areata 35.59 14.41 8 6548 150 29945772
Febrile convulsion 31.45 14.41 9 6547 456 29945466
Asthma 31.18 14.41 39 6517 36135 29909787
Fixed eruption 30.50 14.41 11 6545 1173 29944749
Neonatal hyponatraemia 28.01 14.41 6 6550 89 29945833
Sinusitis 27.23 14.41 35 6521 33310 29912612
Urticaria 25.38 14.41 44 6512 54562 29891360
Hypothermia 25.02 14.41 19 6537 9548 29936374
Erythema 24.47 14.41 53 6503 77398 29868524
Congenital inguinal hernia 20.88 14.41 5 6551 125 29945797
Drug eruption 20.29 14.41 22 6534 17504 29928418
Hypogammaglobulinaemia 19.69 14.41 13 6543 5239 29940683
Allergy to metals 18.99 14.41 3 6553 6 29945916
Periportal oedema 18.70 14.41 4 6552 59 29945863
Neonatal seizure 18.38 14.41 6 6550 474 29945448
Face oedema 18.22 14.41 17 6539 11317 29934605
Eyelid oedema 17.74 14.41 12 6544 5033 29940889
Pemphigoid 17.62 14.41 14 6542 7514 29938408
Rash 17.07 14.41 85 6471 191804 29754118
Erythema multiforme 16.89 14.41 14 6542 7971 29937951
Renal aplasia 16.35 14.41 6 6550 672 29945250
Suspected suicide attempt 15.30 14.41 4 6552 144 29945778
Toxicity to various agents 15.29 14.41 10 6546 177173 29768749
Rash maculo-papular 15.23 14.41 23 6533 25395 29920527
Large for dates baby 14.90 14.41 6 6550 864 29945058
Toxic skin eruption 14.84 14.41 15 6541 11000 29934922
Carbuncle 14.52 14.41 3 6553 37 29945885

Pharmacologic Action:

SourceCodeDescription
ATC R06AE09 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Piperazine derivatives
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
MeSH PA D018377 Neurotransmitter Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Atopic dermatitis off-label use 24079001 DOID:3310
Urticaria off-label use 126485001
Chronic renal failure syndrome contraindication 90688005
Kidney disease contraindication 90708001 DOID:557
Drowsy contraindication 271782001
Hemodialysis with High-Flux Membrane contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.03 acidic
pKa2 8.21 Basic
pKa3 3.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 7.95 WOMBAT-PK CHEMBL

External reference:

IDSource
D07402 KEGG_DRUG
130018-87-0 SECONDARY_CAS_RN
4026739 VANDF
4026740 VANDF
C1174893 UMLSCUI
CHEBI:94559 CHEBI
LCR PDB_CHEM_ID
1549000 PUBCHEM_CID
CHEMBL1201191 ChEMBL_ID
CHEMBL1201190 ChEMBL_ID
DB06282 DRUGBANK_ID
C472067 MESH_SUPPLEMENTAL_RECORD_UI
7700 INN_ID
6U5EA9RT2O UNII
356887 RXNORM
178562 MMSL
18517 MMSL
83855 MMSL
d05851 MMSL
009491 NDDF
009492 NDDF
391595003 SNOMEDCT_US
421889003 SNOMEDCT_US
425461004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-7701 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
good sense levocetirizine HUMAN OTC DRUG LABEL 1 0113-0241 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
levocetirizine HUMAN OTC DRUG LABEL 1 0363-2241 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 0363-5528 TABLET, COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 0363-5529 TABLET, COATED 5 mg ORAL ANDA 15 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1917 SOLUTION 0.50 mg ORAL ANDA 25 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 0536-1144 TABLET, COATED 5 mg ORAL ANDA 15 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-639 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 11673-847 TABLET, COATED 5 mg ORAL ANDA 15 sections
allergy relief HUMAN OTC DRUG LABEL 1 11822-0241 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 11822-5252 TABLET, COATED 5 mg ORAL ANDA 15 sections
Allergy Relief HUMAN OTC DRUG LABEL 1 21130-732 TABLET, COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 30142-717 TABLET, COATED 5 mg ORAL ANDA 15 sections
Levocetirizine Dihydrochloride Human Prescription Drug Label 1 31722-551 TABLET 5 mg ORAL ANDA 24 sections
levocetirizine dihydrochloride Human Prescription Drug Label 1 31722-659 SOLUTION 2.50 mg ORAL ANDA 25 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-947 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
LEVOCETIRIZINE DIHYDROCHLORIDE Human Prescription Drug Label 1 33342-200 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Topcare All Day Allergy HUMAN OTC DRUG LABEL 1 36800-241 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 37808-126 TABLET, COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 41163-938 TABLET, COATED 5 mg ORAL ANDA 14 sections
Xyzal Allergy 24HR HUMAN OTC DRUG LABEL 1 41167-3510 TABLET 5 mg ORAL NDA 15 sections
Childrens Xyzal Allergy HUMAN OTC DRUG LABEL 1 41167-3530 SOLUTION 0.50 mg ORAL NDA 14 sections
Allergy Relief HUMAN OTC DRUG LABEL 1 41250-488 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42291-386 TABLET 5 mg ORAL ANDA 18 sections
levocetirizine dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42543-712 TABLET 5 mg ORAL ANDA 26 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42571-122 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Levocetirizine Dihydrochloride HUMAN OTC DRUG LABEL 1 42571-312 TABLET 5 mg ORAL ANDA 16 sections
Levocetirizine Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43063-479 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 43598-669 TABLET, COATED 5 mg ORAL ANDA 15 sections
levocetirizine dihydrochloride HUMAN OTC DRUG LABEL 1 43598-735 TABLET, COATED 5 mg ORAL ANDA 15 sections